The Impact of Immunisation Programmes on Infectious Diseases in Spain

By HEOR Staff Writer

August 7, 2024

Introduction

Infectious diseases continue to challenge healthcare systems globally. However, effective immunisation strategies and national immunisation programmes (NIP) have proven to be efficient in controlling them. According to the Institute for Health Metrics and Evaluation (IHME), the global burden of infectious diseases decreased significantly from 1990 to 2019. This article will explore the impact of immunisation programmes in Spain, focusing on the burden of selected immunisation-preventable infectious diseases.

The Role of National Immunisation Programmes

National immunisation programmes play a crucial role in reducing the burden of infectious diseases. The European Centre for Disease Prevention and Control (ECDC) initiated the Burden of Communicable Diseases in Europe (BCoDE) project in 2006. This project developed a methodology to assess the impact of infectious diseases on population health in European Union/European Economic Area (EU/EEA) countries. The BCoDE methodology uses Disability-Adjusted Life Years (DALYs) to express the disease burden of an infectious disease. DALYs reflect both the impact on life expectancy and quality of life.

Current Burden of Disease in Spain

Despite immunisation efforts, the burden of certain immunisation-preventable infections remains high in Spain. Respiratory infections, such as influenza, invasive pneumococcal disease, and respiratory syncytial virus (RSV), exhibit the highest burden. Influenza alone accounts for 110.00 annual DALYs per 100,000 population. The burden of invasive pneumococcal disease and RSV follows with 25.20 and 10.57 annual DALYs per 100,000 population, respectively.

In Spanish older adults aged 60 or above, influenza imposes the greatest burden. This is potentially due to a low vaccination coverage rate (VCR), which reached only about 53.5% of those over 64 in the 2019–2020 vaccination campaign. Although this rate is high compared to other European countries, it falls short of the EU goal of 75%.

Figure 1. Burden of selected infectious diseases represented as annual DALYs per 100,000 population. The bars depict the median annual years lived with
disability (YLD) and years of life lost (YLL) per 100,000 population for each infection in Spain

Impact of High Vaccination Coverage Rates

Infections with high VCRs, such as hepatitis B virus (HBV), Haemophilus influenzae, meningococcus, measles, mumps, and varicella, result in a substantially lower disease burden. This highlights the importance of effective public health measures. Maintaining high VCRs can reduce the incidence of some infections to a minimum, as seen with poliomyelitis, rubella, diphtheria, and tetanus in Spain.

Figure 2. Annual burden of selected infectious diseases stratified by sex and age groups. The bars represent the total DALYs per 100,000 population/year for
all the infections evaluated.

Future Directions and Recommendations

The introduction of novel and more effective immunisation strategies could further reduce the burden of high-burden diseases. For instance, the Spanish Society of Geriatrics and Gerontology recommends universal vaccination for all adults ≥ 60 years of age with the high-dose (HD) influenza vaccine. The Spanish Ministry of Health also recommends vaccination for individuals ≥ 65 years, with some regions lowering the threshold to 60 years.

For RSV, the Spanish Association of Paediatrics recommends immunisation of neonates and infants under 6 months at the beginning of their first RSV season, as well as pregnant women. The only efficient preventive strategy in Spain at the time of this study was the single-dose monoclonal antibody nirsevimab.

Conclusion

The results of this analysis highlight a persisting high burden of respiratory infections despite the availability of effective vaccines and immunisation recommendations. Increasing VCRs and introducing novel immunisation strategies could further reduce this burden. Maintaining high VCRs for low-burden diseases is essential to prevent outbreaks and keep these diseases under control. These estimates provide a basis to guide prevention strategies, prioritise interventions, and make public health decisions in Spain.

Reference url

Recent Posts

NICE Kidney Cancer Guideline: Enhancing Biopsy Use to Minimize Unnecessary Surgery

By João L. Carapinha

September 18, 2025

The NICE kidney cancer guideline represents a major shift in how renal cell carcinoma is diagnosed and managed in the UK. How does this guideline change the standard of kidney cancer care? By emphasizing more accurate diagnosis—especially the targeted use of kidney biopsies—it aims to avoid unnec...
CAPVAXIVE Pneumococcal Vaccine Delivers Strong Immune Response in At-Risk Youth

By HEOR Staff Writer

September 17, 2025

What makes the CAPVAXIVE pneumococcal vaccine significant for children and adolescents at higher risk for pneumococcal disease? The CAPVAXIVE pneumococcal vaccine (21-valent conjugate vaccine) demonstrated robust immune responses and broad serotype coverage in Merck’s Phase 3 STRIDE-13 trial. ...
Oral Semaglutide Benefits: EMA Approves First Oral GLP-1 RA with Cardiovascular Perks

By HEOR Staff Writer

September 16, 2025

Novo Nordisk’s oral semaglutide (Rybelsus®) has received a significant label update from the European Medicines Agency (EMA). It is now the first and only oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved in the EU for type 2 diabetes with proven cardiovascular benefits. This deci...